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INTRODUCTION
The SLC25A13 gene on chromosome 7q21.3 is known to
be responsible for adult-onset type II citrullinemia (CTLN2).
The SLC25A13 gene consists of 18 exons and encodes a liver-
type mitochondrial aspartate-glutamate carrier named citrin (1,
2), which plays an important role in malate-aspartate NADH
shuttling, urea synthesis, and gluconeogenesis. CTLN2 is char-
acterized by late-onset hyperammonemia and neuropsychiatric
symptoms, such as disorientation, delirium, delusion, and dis-
turbed consciousness (3). Ohura et al. (4) and Tazawa et al. (5)
demonstrated that mutations in the SLC25A13 gene cause
neonatal intrahepatic cholestasis and transient citrullinemia,
which has been designated as neonatal intrahepatic cholesta-
sis caused by citrin deficiency (NICCD; OMIM 605814) (6).
NICCD is characterized by multiple amino acidemia (involv-
ing citrulline, threonine, methionine, arginine, and tyrosine),
galactosemia, hypoproteinemia, hypoglycemia, cholestasis, and
fatty liver. Most NICCD patients show ameliorated symptoms
within 1 yr of age and require no further special treatment
other than feeding programs. However, several decades later
some patients develop CTLN2 (7, 8). 
Initially, NICCD was identified exclusively in the Japanese
population, but recently the disease has been reported in Pales-
tinians (9), Vietnamese (10), and Taiwanese infants (11). Fur-
thermore, a population analysis showed that the carrier rate
of mutations in SLC25A13 among Koreans was 1 in 112 (11).
There has been no report of NICCD in Korea. In the present
study, the authors investigated clinical findings of Korean in-
fants with NICCD and performed mutation analysis on the
SLC25A13 gene.
MATERIALS AND METHODS
Patients
Between 2005 and 2006, 47 patients were admitted to
the Department of Pediatrics in Seoul National University
Children’s Hospital for neonatal cholestasis. Examinations
included abdominal ultrasonography, duodenal intubation,
a hepatobiliary scan, and liver biopsy. Total parenteral nutri-
tion, drug-related cholestasis, and cholestasis secondary to
sepsis were excluded. 
NICCD was diagnosed based on the presence of hyper-
amino acidemia, galactosemia, fatty liver, and on the results
of the genetic study detailed below. Patients with NICCD
were followed until at least 18 months of age.
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Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency in
Korean Infants
Citrin is a liver-type mitochondrial aspartate-glutamate carrier encoded by the
SLC25A13 gene, and its deficiency causes adult-onset type II citrullinemia and
neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). Here, the
authors investigated clinical findings in Korean infants with NICCD and performed
mutation analysis on the SLC25A13 gene. Of 47 patients with neonatal cholesta-
sis, three infants had multiple aminoacidemia (involving citrulline, methionine, and
arginine) and galactosemia, and thus were diagnosed as having NICCD. Two of
these three showed failure to thrive. The laboratory findings showed hypoproteine-
mia and hyperammonemia, and liver biopsies revealed micro-macrovesicular fatty
liver and cholestasis. The three patients each harbored compound heterozygous
1,638-1,660 dup/ S225X mutation, compound heterozygous 851del4/S225X muta-
tion, and heterozygous 1,638-1,660 dup mutation, respectively. With nutritional
manipulation, liver functions were normalized and catch-up growth was achieved.
NICCD should be considered in the differential diagnosis of cholestatic jaundice in
Korean infants.
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Genetic study
Genomic DNA was extracted from peripheral blood using
Wizard genomic DNA purification kits, according to the man-
ufacturer’s instructions (Promega, Madison, WI, U.S.A.). In-
formed consent was obtained from all parents. Mutations of
the SLC25A13 gene were detected by using previously desc-
ribed primers (11, 12). Seven different primer sets were used
to detect the 12 known mutations of SLC25A13 by polymerase
chain reaction (PCR), namely, IVS8F2 and Ex9B, mutation [I]
(851del4); Ex11F2 and IVS11Bm2, mutation [II] (IVS11+
1G>A); IVS15F2 and Ex16B, mutation [III] (1,638-1,660
dup); IVS6F and IVS7B, mutation [IV] (S225X); Ex13F and
IVS13Bm, mutation [V] (IVS13+1G>A); IVS16F and IV-
S17B, mutation [VI](1800ins1), mutation [VII](R605X), mu-
tation [VIII] (E601X), and mutation [IX] (E601K); IVS5NF
and IVS6NB, mutation [X] (IVS6+5G>A), mutation [XI]
(R184X), and mutation [XIV](IVS6+1G>C). PCR was per-
formed using 1 cycle at 94℃for 1 min, 30 amplification cycles
(94℃ for 30 sec, 50℃ for 30 sec, and 72℃ for 30 sec), fol-
lowed by 72℃for 5 min. Forward and reverse strands of PCR
products were direct-sequenced using the above-mentioned
PCR primers on the ABI 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, U.S.A.). Sequences obtained were
compared with the reference sequence NM-014251 registered
in the National Center for Biotechnology Information database
(http://www. ncbi.nlm.nih.gov).
RESULTS
Among the 47 patients with neonatal cholestasis present-
ed during the two-year period, extrahepatic biliary atresia was
diagnosed in 11, congenital infection with TORCH in 4, pro-
gressive familial intrahepatic cholestasis (PFIC) in 2, ARC
(arthrogryposis, renal dysfunction, cholestasis) syndrome in
2, neonatal Dubin-Johnson syndrome in 2, Alagille syndrome
in 1, and non-syndromic bile duct paucity in 1. No etiology
was identified in 21 patients (Table 1).
NICCD was diagnosed in three patients. Table 2 summa-
rizes the genotype and clinical and laboratory findings of these
three patient. Birth weights ranged from 2.7 to 3.1 kg. The
chief complaint was cholestatic jaundice in all patients, and
all were referred for suspected neonatal hepatitis or biliary atre-
sia. Two infants were referred at 3 months of age and one infant
at 7 months. Two infants showed failure to thrive at initial
presentation. Newborn tandem mass screening performed on
case 2 at 1 week of age was normal. Total serum protein lev-
els were reduced in two patients. Blood ammonia levels were
slightly increased in all three, and gamma glutamyltranspep-
tidase and alkaline phosphatase were markedly elevated in all
three, whereas alanine aminotransferase levels were slightly
increased in two. Hypoglycemia was present in case 1. Alpha-
fetoprotein levels were high and galactosemia was detected
in all patients. Plasma amino acid analyses showed that cit-
rulline, methionine, and arginine were significantly elevated
in all three. Plasma tyrosine, threonine, and lysine were ele-
vated in two (Table 3). No patient had a bleeding tendency
or a cataract.
NICCD, neonatal intrahepatic cholestasis caused by citrin deficiency;
ARC syndrome, arthrogryposis, renal dysfunction, cholestasis syndrome.
Diagnosis No  (%)
Extrahepatic biliary atresia 11 (23)
TORCH infection 4 (9)
NICCD 3 (6)
Progressive familial intrahepatic cholestasis 2 (4)
ARC syndrome 2 (4)
Dubin-Johnson syndrome 2 (4)
Alagille syndrome 1 (2)
Non-syndromic bile duct paucity 1 (2)
Idiopathic 21 (45)
Table 1. Differential diagnosis of neonatal cholestasis
Case Age (mo) Weight 
(kg)
TB/DB
(mg/dL)
AST/ALT
(IU/L)
Protein
(g/dL)
-GT 
(IU/L)
-fetoprotein
(ng/mL)
NH3
( g/dL)
Genotype
1 3 5.7 5.4/3.2 145/48 135 5.2 109 84,000 III/(-)
2 3 4.6 5.2/3.2 238/158 263 5.1 89 29,500 I/IV
3 7 6.4 4.5/2.7 115/70 148 6.1 76 44,700 III/IV
Normal value <1.2/<0.5 <40/<40 < 63 >6.0 <75 <55
Table 2. Clinical and laboratory findings, and the genotypes of the 3 NICCD patients
NICCD, neonatal intrahepatic cholestasis caused by citrin deficiency; TB, total bilirubin; DB, direct bilirubin; AST, aspartate aminotransferase; ALT,
alanine aminotransferase.
SLC25A13 mutations I, III, and IV are 851del4, 1,638-1,660 dup, and S255X, respectively.
NICCD, neonatal intrahepatic cholestasis caused by citrin deficiency;
amino acid, M/L; galactose, mg/dL.
Case
Galac-
tose
Ly-
sine
Tyro-
sine
Argi-
nine
Threo-
nine
Methio-
nine
Citru-
lline
1 301 73 553 397 215 332 162
2 186 106 216 215 248 246 14
3 93 64 168 120 100 166 26 
Refe- 8-47 3-43 20-204 12-112 19-119 66-270 <8
rence
Table 3. Plasma amino acid and galactose levels in the 3 NICCD
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Liver biopsy was performed in two patients. Cholestasis
and micro-macrovesicular fatty change were observed in these
two, and moderate periportal fibrosis was present in case 3. 
Five of the six alleles (83%) examined showed mutations. In
detail, compound heterozygous 1,638-1,660 dup/S255X
mutation (mutation [III]/[IV]), compound heterozygous
851del4/ S225X mutation (mutation [I]/[IV]), and heterozy-
gous 1,638-1,660 dup mutation (mutation [III]) were found
in each patient. The allele frequencies of mutations [I], [III],
and [IV] were 17%, 33%, and 33%, respectively.
Lactose-free soy formula and a medium chain triglyceride
(MCT) formula were fed to all patients. Fat-soluble vitamins
were added. Within 2 months of diagnosis, plasma amino acid
profiles were normalized, whereas liver functions were nearly
normalized at the age of 9 to 13 months. At the age of 18 mo-
nths, catch-up growth had been achieved by all three patients.
DISCUSSION
Citrullinemia is categorized as CTLN1 (classical neonatal
onset) or as CTLN2 (adult onset). CTLN1 is an autosomal
recessive disease that is caused by a deficiency of arginiosuc-
cinate synthetase, and is characterized by a neonatal-onset
and severe hyperammonemia, irritability, lethargy, poor feed-
ing, and tachypnea (13). On the other hand, CTLN2 is an
autosomal recessive disease caused by citrin deficiency, and is
characterized by late onset (11 to 79 yr), frequent attacks of
hyperammonemia, and mental derangement, and leads to
death within a few years from the onset (3). The SLC25A13
gene, which encodes citrin, has been found to be defective in
CTLN2. In the liver, citrin participates in the urea cycle by
supplying aspartate from mitochondria to the cytosol for the
incorporation into argininosuccinate. Lack of aspartate for ar-
gininosuccinate synthesis under citrin deficiency probably caus-
es citrulline accumulation (14). Previous DNA analyses have
shown that some infants with idiopathic neonatal hepatitis
harbor the same mutations in SLC25A13 as CTLN2 patients
(4, 5), and these infants had cholestasis, hyperaminoacidemia,
galactosemia, hypoproteinemia, and hepatic steatosis. On new-
born tandem mass screening, about a half of NICCD patients
were detected because of high citrulline, galactose, phenylala-
nine, and/or methionine concentrations (15, 16).
In the present study, NICCD accounted for approximately
6% (3/47) of our cohort of neonatal cholestatic liver disease.
Other hereditary intrahepatic cholestasis including PFIC, Alag-
ille syndrome, ARC syndrome, and Dubin-Johnson syndrome
were found in 15%. The study shows that genetic intrahe-
patic cholestasis is a common cause of neonatal cholestasis in
Korean infants. The initial evaluations of infants with cholesta-
sis include ultrasonography, duodenal intubation, and percu-
taneous liver biopsy, in order to exclude biliary atresia. Liver
biopsy is also useful for detecting Alagille syndrome, Dubin-
Johnson syndrome, and PFIC. Serum  -GT is also helpful be-
cause low levels of  -GT in the presence of cholestasis suggest
PFIC or ARC syndrome. Our data suggest that plasma amino
acid analysis is useful for the screening for metabolic diseases,
such as NICCD.
In the present study, NICCD patients presented with cho-
lestatic jaundice and failure to thrive. Laboratory findings
showed mild hyperammonemia, hypoproteinemia, and galac-
tosemia. Citrin deficiency blocks the malate-aspartate shut-
tle, which may increase the cytosolic NADH-to-oxidized
nicotinamide adenine dinucleotide ratio (NADH/NAD
+).
Since uridine diphosphate-galactose epimerase, which re-
quires NAD
+ as a cofactor, is strongly inhibited by NADH,
a high level of NADH in liver cytosol may underlie the eti-
ology of galactosemia in NICCD (14).
Hypoglycemia was detected in one patient. Citrin functions
to provide substrates for gluconeogenesis as a component of
the pathway responsible for converting amino acids to glucose
(3). In the present study, plasma amino acid analysis showed
that the concentrations of citrulline, methionine, threonine,
arginine, and/or tyrosine were elevated. One of our three pa-
tients did not show an abnormal amino acid profile on new-
born mass screening at 7 days of age. Tandem mass screening
data in Japan suggest that the incidence of NICCD is approx-
imately 1 in 34,000 (15), but the frequency of homozygotes
with mutated SLC25A13 has been estimated to be 1 in 19,000
(17). Tamamori et al. (16) demonstrated that NICCD patients
with negative newborn mass screening findings have lower
total amino acid levels, and that citrulline/total amino acids
ratios can offset the effect of low total amino acids.
This is the first report of genetically confirmed NICCD in
a Korean cohort. The mutation rate observed in three NICCD
patients was 83%, which is similar to that reported in Taiwan-
ese patients (18). In the present study, the allele frequencies of
mutation [I], [III], and [IV]were 17%, 33%, and 33%, respec-
tively. Screening of 12 mutations in Korean control individ-
uals showed that mutation [I] and [II] were found to be most
common, and mutation [III] accounted for 5% of total muta-
tions, but mutation [IV] was absent (11). A Japanese study
found that the frequency of mutation [IV] differs in NICCD
patients and controls (6). However, since the number of patients
with NICCD was comparatively small in the present study,
further mutation studies are needed. To date only one adult
case of CTLN2 has been reported in Korea (19); the patient
presented with insomnia and lethargy at 55 yr of age. How-
ever, the theoretical frequency of homozygotes calculated from
carrier rates in Koreans is 1 in 50,000 (11), which suggests
that NICCD and CTLN2 are substantially under diagnosed
in Korea.
The management of NICCD is directed toward treating
the consequences of cholestasis and galactosemia. MCT for-
mula and supplementation with fat-soluble vitamins have
been used to prevent complications of prolonged cholestasis.
It should be noted that lactose may be toxic to NICCD pa-
tients and should be avoided while cholestasis persists (20).Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency 955
The prognosis of our patients was good because liver func-
tions were normalized before 13 months of age and catch-up
growth was achieved at 18 months. The amelioration of
NICCD symptoms over a year suggests hepatocyte matura-
tion and some adaptation or compensation by other mito-
chondrial carriers (14). One of our three patients showed
moderate periportal fibrosis on liver histology. Mild to mod-
erate portal fibrosis has been previously observed in NICCD
(5, 7). Liver function was normalized in this patient, but his
clinical course needs to be carefully monitored. One NICCD
patient developed liver failure and underwent liver trans-
plantation at 11 months of age (21). It should be noted that
some NICCD patients develop CTLN2 at their twenties or
even several decades later (7, 8). Although the prognosis of
CTLN2 is poor, liver transplantation is remarkably effective
(3). As yet, it cannot be determined which NICCD patients
will later develop CTLN2, and thus, all NICCD patients
should be followed for signs of development of CTLN2.
The present study indicates that NICCD should be con-
sidered in the differential diagnosis of cholestatic jaundice in
Korean infants, and that plasma amino acid analysis should
be included in the evaluation of infantile intrahepatic chole-
stasis. Moreover, the findings of SLC25A13 genetic studies
were found to be useful for confirming the diagnosis of NICCD.
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